MULTIPLE SCLEROSIS - THE GUIDE TO TREATMENT AND MANAGEMENT British Journal of Occupational TherapyJewell, Carol B
Multiple Sclerosis: The Guide for Treatment and Management, Fifth Edition : Chris H. Polman, Alan J. Thompson, J. Jock Murray, I. Ian McDonald. Demos Medical Publishing, New York, 2001, 148 pp., ISBN 1-888799-54-4, $24.95No abstract is available for this article....
How much do multiple sclerosis treatments cost? Treating multiple sclerosis costs a great deal for patients and communities. Individually, the nearly 1 million people with MS pay an average annual cost of more than $88,000 for the various treatment options, devices, daily living needs, and insur...
The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
infiltrate[155]. Other studies have shown that the pregnancy hormoneestriolcan ameliorateEAEin mice with an increased production of the Th2 cytokine IL I0 [156], and human studies evaluating the use of estriol as a treatment for multiple sclerosis have initially produced encouraging results [157]...
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT Autologous haematopoietic stem cell transplantation (AHSCT) is a treatment option for some forms of multiple sclerosis (MS), but unce...
Multiple Sclerosis: A Guide to Treatment and ManagementWriting a book in a quickly changing field becomes a difficult taskfor an author. Within the last decade, the basic concepts of many...
Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating and neurodegenerative disease of the central nervous system in young adults. This disorder is a heterogeneous, multifactorial, immune-mediated disease that is influenced by bo
Improvement of spasticity with dantrolene sodium in multiple sclerosis has been reliably reported to range from 30% to 40%.1 The results reported by Tolosa et al are in the same "ball park." The complexity of the mechanism of this disease is well known. Attainment of such results in 30% ...
W. et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 49, 351–357 (1997). PubMed Google Scholar Mundt, S. et al. Conventional DCs sample and present ...